Avior Wealth Management LLC Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Avior Wealth Management LLC increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,858 shares of the medical equipment provider’s stock after buying an additional 309 shares during the period. Avior Wealth Management LLC’s holdings in Lantheus were worth $363,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Tucker Asset Management LLC raised its position in Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares during the period. Parkside Financial Bank & Trust raised its position in Lantheus by 60.2% during the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 160 shares during the period. First Horizon Advisors Inc. grew its stake in shares of Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 225 shares during the last quarter. Covestor Ltd grew its stake in Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 203 shares in the last quarter. Finally, Coppell Advisory Solutions LLC bought a new position in Lantheus in the second quarter worth approximately $46,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders sold 94,545 shares of company stock worth $6,169,936 in the last 90 days. Insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH opened at $63.81 on Friday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $100.85. The stock has a fifty day moving average price of $60.81 and a 200-day moving average price of $62.97. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. The firm has a market cap of $4.37 billion, a PE ratio of 13.75 and a beta of 0.53.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. Equities research analysts predict that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial reissued a “buy” rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Finally, B. Riley upped their target price on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $104.71.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.